NCT04368390

Brief Summary

To describe the radiological presentation of brain abnormalities in COVID-19 + patients

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Apr 2020

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 3, 2020

Completed
25 days until next milestone

First Submitted

Initial submission to the registry

April 28, 2020

Completed
1 day until next milestone

First Posted

Study publicly available on registry

April 29, 2020

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2021

Completed
Last Updated

December 24, 2020

Status Verified

April 1, 2020

Enrollment Period

12 months

First QC Date

April 28, 2020

Last Update Submit

December 22, 2020

Conditions

Covid-19

Keywords

COVID-19MRIBrain

Outcome Measures

Primary Outcomes (1)

  • Neuroradiological analysis of patients brain MRI

    1 year

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients COVID-19 with abnormal neurological examination

You may qualify if:

  • Adults
  • COVID-19 +
  • Abnormal neurological examination
  • who underwent a brain MRI

You may not qualify if:

  • No participation agreement
  • Non COVID-19 patients
  • Patients COVID-19 + without neurological abnormality or without MRI examination

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Service d'Imagerie 2 - Neuroradiologie

Strasbourg, 67091, France

RECRUITING

Related Publications (1)

  • Kremer S, Lersy F, Anheim M, Merdji H, Schenck M, Oesterle H, Bolognini F, Messie J, Khalil A, Gaudemer A, Carre S, Alleg M, Lecocq C, Schmitt E, Anxionnat R, Zhu F, Jager L, Nesser P, Mba YT, Hmeydia G, Benzakoun J, Oppenheim C, Ferre JC, Maamar A, Carsin-Nicol B, Comby PO, Ricolfi F, Thouant P, Boutet C, Fabre X, Forestier G, de Beaurepaire I, Bornet G, Desal H, Boulouis G, Berge J, Kazemi A, Pyatigorskaya N, Lecler A, Saleme S, Edjlali-Goujon M, Kerleroux B, Constans JM, Zorn PE, Mathieu M, Baloglu S, Ardellier FD, Willaume T, Brisset JC, Caillard S, Collange O, Mertes PM, Schneider F, Fafi-Kremer S, Ohana M, Meziani F, Meyer N, Helms J, Cotton F. Neurologic and neuroimaging findings in patients with COVID-19: A retrospective multicenter study. Neurology. 2020 Sep 29;95(13):e1868-e1882. doi: 10.1212/WNL.0000000000010112. Epub 2020 Jul 17.

    PMID: 32680942DERIVED

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Central Study Contacts

Stephane Kremer, MD, PhD

CONTACT

33 3 88 12 78 89stephane.kremer@chru-strasbourg.fr

Saïd CHAYER, PhD, HDR

CONTACT

33 3 88 11 66 90said.chayer@chru-strasbourg.fr

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
OTHER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 28, 2020

First Posted

April 29, 2020

Study Start

April 3, 2020

Primary Completion

April 1, 2021

Study Completion

April 1, 2021

Last Updated

December 24, 2020

Record last verified: 2020-04

Locations

FR(1)